Inovio Biomedical receives Korean approval for Phase I clinical trial of DNA vaccine

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Research and Markets: The Report 'PV Innovation in North America'...
Research and Markets: Vietnam Telecommunications Services Market Report:...
Research and Markets: Indonesia Soft Drinks Review 2011: consumption,...
Northampton family thank Red Cross with generous donation to county...
Research and Markets: Malaysia Soft Drinks Review 2011: consumption,...
Simon Ward - The MPC is making another policy...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Inovio Biomedical receives Korean approval for Phase I clinical trial of DNA vaccine
3 March 2010 - US-based biomedical company Inovio Biomedical Corporation (AMEX: INO) said yesterday that its affiliate VGX International Inc (SEO:011000) has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for SynCon preventive DNA vaccine (VGX-3400) targeting...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search